Effectiveness of Trimetazidine in Patients with Stable Angina Pectoris of Various Durations: Results from ODA
- PDF / 789,809 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 57 Downloads / 194 Views
ORIGINAL RESEARCH
Effectiveness of Trimetazidine in Patients with Stable Angina Pectoris of Various Durations: Results from ODA Maria G. Glezer . Vladimir A. Vygodin on behalf of ODA investigators
Received: April 24, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Trimetazidine (TMZ) is an antianginal agent that acts directly at the myocardial cell level and which is now available in a once-daily (od) formulation. Methods: ODA, a 3-month, observational, multicenter study in Russia, assessed the effectiveness and tolerability of TMZ 80 mg od in patients with stable angina and persisting symptoms, in real-life settings. The present analysis explored the effects of adding TMZ to background antianginal treatment with respect to the duration of stable angina.
Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12162033. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40119020-00174-7) contains supplementary material, which is available to authorized users. M. G. Glezer (&) Department of Cardiology, Functional and Ultrasonic Diagnostics, Sechenov First Moscow State Medical University, Moscow, Russia e-mail: [email protected] V. A. Vygodin Laboratory of Biostatistics, National Medical Research Center for Preventive Medicine of the Ministry of Healthcare, Moscow, Russia
Results: A total of 3032 patients were divided into four groups according to stable angina pectoris duration since diagnosis, ranging from less than 1 year to more than 10 years. A decrease in frequency of angina attacks was observed, including in patients with angina duration \ 1 year, in whom the frequency of weekly angina attacks decreased from 3.8 ± 2.9 to 1.4 ± 1.7 at 1 month and 0.6 ± 1.0 at 3 months. Short-acting nitrate consumption and proportion of angina-free patients decreased, and self-reported physical activity and adherence to antianginal therapy improved in all patient groups, including recently diagnosed patients and starting already at month 1. Conclusions: Addition of TMZ 80 mg od to antianginal treatment was effective in reducing the frequency of angina attacks and the use of short-acting nitrates, improving Canadian Cardiovascular Society (CCS) class, self-reported physical activity, and adherence to antianginal therapy. These beneficial effects were observed in patient groups with different durations of stable angina, suggesting an opportunity for decreasing angina burden even in recently diagnosed patients. Trial Registration: ISRCTN registry Identifier, ISRCTN97780949. Keywords: Chronic coronary syndrome; Diagnosis duration; Observational study; Realworld evidence; Stable angina; Trimetazidine
Cardiol Ther
Key Summary Points Why carry out this study? Trimetazidine (TMZ) is an antianginal treatment whose efficacy has been demonstrated in randomized clinical trials, and which is now available in an 80-mg one-daily (od) dosage. In this analysis, the effect of TMZ addition to hemodynamic therapy was assessed in patient groups with differe
Data Loading...
